Humacyte Valuation
| HUMA Stock | USD 2.73 0.43 18.70% |
Based on Macroaxis valuation methodology, the firm appears to be overvalued. Humacyte retains a regular Real Value of $2.36 per share. The prevalent price of the firm is $2.73. Our model calculates the value of Humacyte from evaluating the firm fundamentals such as Return On Equity of -2.5, shares outstanding of 155.12 M, and Return On Asset of -0.43 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Humacyte's price fluctuation is dangerous at this time. Calculation of the real value of Humacyte is based on 3 months time horizon. Increasing Humacyte's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Humacyte is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Humacyte Stock. However, Humacyte's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.73 | Real 2.36 | Hype 2.73 | Naive 2.27 |
The real value of Humacyte Stock, also known as its intrinsic value, is the underlying worth of Humacyte Company, which is reflected in its stock price. It is based on Humacyte's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Humacyte's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Humacyte helps investors to forecast how Humacyte stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Humacyte more accurately as focusing exclusively on Humacyte's fundamentals will not take into account other important factors: Humacyte Total Value Analysis
Humacyte is currently expected to have valuation of 309.78 M with market capitalization of 356.77 M, debt of 16.54 M, and cash on hands of 189.04 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Humacyte fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
309.78 M | 356.77 M | 16.54 M | 189.04 M |
Humacyte Asset Utilization
One of the ways to look at asset utilization of Humacyte is to check how much profit was generated for every dollar of assets it reports. Humacyte retains a negative application of resources of -0.43 (percent), losing $0.004282 for each dollar of resources held by the firm. Inadequate asset utilization attests that the company is being less effective with each dollar of resources it retains. Simply put, asset utilization of Humacyte shows how discouraging it operates for each dollar spent on its resources.Humacyte Ownership Allocation
Humacyte has a total of 155.12 Million outstanding shares. Humacyte secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. On June 13, 2024, Senator Tommy Tuberville of US Senate acquired $15k to $50k worth of Humacyte's common stock.Humacyte Profitability Analysis
Net Loss for the year was (148.7 M) with loss before overhead, payroll, taxes, and interest of (82.38 M).Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Humacyte's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Humacyte and how it compares across the competition.
About Humacyte Valuation
The stock valuation mechanism determines Humacyte's current worth on a weekly basis. Our valuation model uses a comparative analysis of Humacyte. We calculate exposure to Humacyte's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Humacyte's related companies.Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company was founded in 2004 and is headquartered in Durham, North Carolina. Humacyte operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 145 people.
Humacyte Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 118.5 M |
Complementary Tools for Humacyte Stock analysis
When running Humacyte's price analysis, check to measure Humacyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Humacyte is operating at the current time. Most of Humacyte's value examination focuses on studying past and present price action to predict the probability of Humacyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Humacyte's price. Additionally, you may evaluate how the addition of Humacyte to your portfolios can decrease your overall portfolio volatility.
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |